Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4197.50 +0.7% SILVER 57.55 +0.7% COPPER 6.60 +0.6% OIL 95.82 −2.2% PALLADIUM 1122.50 −0.5% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.670 +3.1% LIB 0.720 +0.0% NPR 0.640 +3.2% QZM 0.380 +0.0% BVA 0.750 −1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.355 +4.4% PHNM 0.345 +1.5% SLG 5.60 −1.9% CASA 0.065 +8.3% DRY 0.225 +4.7% SOMA 0.570 +1.8% GOLD 4197.50 +0.7% SILVER 57.55 +0.7% COPPER 6.60 +0.6% OIL 95.82 −2.2% PALLADIUM 1122.50 −0.5% MON 0.385 −6.1% OMI 0.250 +0.0% BUFF 0.800 +2.6% FEO 0.670 +3.1% LIB 0.720 +0.0% NPR 0.640 +3.2% QZM 0.380 +0.0% BVA 0.750 −1.3% ONAU 0.530 +1.9% FMR 0.225 +0.0% GSVR 0.355 +4.4% PHNM 0.345 +1.5% SLG 5.60 −1.9% CASA 0.065 +8.3% DRY 0.225 +4.7% SOMA 0.570 +1.8%
Earnings

Else Nutrition's Q3 revenues at $1.66-million

By The Northwire Desk — AI Analysis Nov 14, 2025 · 15:16 BABY · 0.12 Else Nutrition Holdings Inc
BABY · Price

Executive Summary

  • Else Nutrition reported a dramatic operational turnaround in Q3 2025, with gross margin expanding to 34% (up from –9% YoY) and operating expenses falling 68% year‑over‑year.
  • Operating loss narrowed to $580k, while revenue held steady at $1.66 M despite temporary out‑of‑stock issues.
  • Cash on hand was $91k and trade payables were reduced by 46% to $1.53 M, improving liquidity and debt‑management capacity.

Key Details

  • Gross Profit Margin: 34% in Q3 2025 vs. –9% in Q3 2024 and –4% in Q2 2025.
  • Operating Expenses: $1.15 M in Q3 2025 (down from $3.56 M in Q3 2024), a 68% YoY reduction.
  • Operating Loss: $580,000 in Q3 2025 vs. $3.72 M loss in Q3 2024.
  • Revenue: $1.66 M in Q3 2025 (slightly down from $1.79 M in Q3 2024).
  • Cash Position: $91,000 at quarter‑end (includes restricted cash).
  • Trade Payables: Decreased 46% to $1.53 M as of Sept. 30 2025 (from $2.84 M on Dec. 31 2024).
  • Management Commentary: CEO Hamutal Yitzhak highlighted cost‑optimization, manufacturing transition, and progress toward profitability; noted ongoing regulatory modernization for U.S. infant formula and preparation for next clinical phase of plant‑based infant formula.
  • Strategic Initiatives: Engaging international partners for commercial, R&D, and manufacturing collaborations; focusing on supply‑chain resolution, retail/online expansion, and regulatory milestones.
  • Conference Call: Business update scheduled for Monday, Nov 17 2025 at 10:00 a.m. ET; dial‑in numbers provided, webcast replay available through Sept 17 2026, telephone replay by Dec 1 2025.

Notable Quotes

“We delivered a dramatic improvement in our fundamentals. Our gross margin expansion to 34 per cent and a 68‑per‑cent reduction in operating expenses demonstrate the effectiveness of our restructuring and cost‑control initiatives.” – Hamutal Yitzhak, CEO

Materiality Assessment: Material – Positive** (The release contains significant financial improvements and forward‑looking operational guidance.)

Read the original news release →

More from Else Nutrition Holdings Inc

Jun 29, 2026 · 07:30

Else Nutrition Announces CSE Conditional Approval

Financings Jun 01, 2026 · 07:45

Else Nutrition Initiates Q2 Manufacturing Drive to Cure Chronic Stockouts as TSX Delisting Looms and CSE Listing Transition Begins

Production / Operations May 15, 2026 · 13:44

Else Nutrition Margins Improve But Liquidity Crunch and TSX Delisting Signal Continued Distress

Earnings May 07, 2026 · 13:55

Distressed Exchange Transition

Regulatory Apr 15, 2026 · 07:30

Else Nutrition Regulatory Wins Fail to Halt Penny Stock Slide Amid Cash Burn Concerns

Regulatory Mar 10, 2026 · 16:36

Else looks to develop potential infant formula in U.S.

Regulatory